



# COMPARATIVE EFFECTIVENESS RESEARCH

## A Selected List of Publications by Thomson Reuters Researchers

Thomson Reuters researchers work with academic, government, payer, provider, biopharmaceutical, and medical technology clients on a variety of healthcare projects, including those related to comparative effectiveness research (CER). Below is a bibliography of CER studies published in peer-reviewed journals. Authors in bold are Thomson Reuters researchers or were at the time of publication.

### 2011

---

**Carls GS, Gibson TB**, Driver VR, Wrobel JS, Garoufalidis MG, Defrancis RR, **Wang S, Bagalman JE**, Christina JR. The economic value of specialized lower-extremity medical care by podiatric physicians in the treatment of diabetic foot ulcers. *Journal of the American Podiatric Medical Association* 2011; 101(2): 93–115.

Harnett J, **Margolis J, Cao Z, Fowler R**, Sanchez RJ, Mardekian J, Silverman SL. Real-world evaluation of healthcare resource utilization and costs in employees with fibromyalgia treated with pregabalin or duloxetine. *Pain Practice* 2011; 11(3): 217–29.

**Mark TL**, Joish VN, Hay JW, Sheehan DV, **Johnston SS, Cao Z**. Antidepressant use in geriatric populations: The burden of side effects and interactions and their impact on adherence and costs. *American Journal of Geriatric Psychiatry* 2011; 19(3): 211–21.

Thomas CP, Garnick DW, Horgan CM, McCorry F, Gmyrek A, Chalk M, Gastfriend DR, Rinaldo SG, Albright J, Capoccia VA, Harris AH, Harwood HJ, Greenberg P, **Mark TL**, Un H, Oros M, Stringer M, Thatcher J, Cotter F, Stein J. Advancing performance measures for use of medications in substance abuse treatment. *Journal of Substance Abuse Treatment* 2011; 40(1): 35–43.

### 2010

---

Amin AN, Lin J, **Johnson BH, Schulman KL**. Clinical and economic outcomes with appropriate or partial prophylaxis. *Thrombosis Research* 2010; 125(6): 513–7.



- Bonafede MM**, Kalsekar A, Pawaskar M, **Ruiz KM**, **Torres AM**, Kelly KR, **Curkendall SM**. A retrospective database analysis of insulin use patterns in insulin-naïve patients with type 2 diabetes initiating basal insulin or mixtures. *Patient Preference and Adherence* 2010; 4: 147–56.
- Durden E**, **Bagalman E**, Muser E, Choi JC, Crivera C, Dirani R, Macfadden W, Haskins JT. Characteristics, healthcare utilization and costs of bipolar disorder type I patients with and without frequent psychiatric intervention in a Medicaid population. *Journal of Medical Economics* 2010;13(4): 698–704.
- Gibson TB**, Jing Y, Kim E, **Bagalman E**, **Wang S**, Whitehead R, Tran QV, Doshi JA. Cost-sharing effects on adherence and persistence to second-generation antipsychotics in commercially-insured patients. *Managed Care* 2010; 40–47.
- Gibson TB**, **Song X**, Alemayehu B, **Wang S**, **Waddell J**, Bouchard J, Forma F. Cost-sharing, adherence, and health outcomes in patients with diabetes. *American Journal of Managed Care* 2010; 16(8): 589–600.
- Goetzel RZ**, **Gibson TB**, Short ME, Chu BC, **Waddell J**, Bowen J, Lemon SC, Fernandez ID, Ozminkowski RJ, Wilson MG, DeJoy DM. A multi-worksite analysis of the relationships among body mass index, medical utilization and worker productivity. *Journal of Occupational and Environmental Medicine* 2010; 52(1S): 52.
- Goetzel RZ**, Roemer EC, **Pei X**, **Short ME**, **Tabrizi MJ**, Wilson MG, Dejoy DM, Craun BA, Tully KJ, White JM, Baase CM. Second-year results of an obesity prevention program at the Dow Chemical Company. *Journal of Occupational and Environmental Medicine* 2010; 52(3): 291–302.
- Kelly E, **Carls GS**, **Lenhart G**, Mauceri E, Columbus D, Cavuoti A, **Goetzel RZ**. The Novartis health index: A method for valuing the economic impact of risk reduction in a workforce. *Journal of Occupational and Environmental Medicine* 2010; 52(5): 528–35.
- Kowlessar NM, **Henke RM**, **Goetzel RZ**, Colombi AM, Felter EM. The influence of worksite health promotion program management and implementation structure variables on medical care costs at PPG Industries. *Journal of Occupational and Environmental Medicine* 2010; 52(12): 1160–6.
- Margolis J**, **Cao Z**, **Fowler R**, Harnett J, Sanchez RJ, Mardekian J, Silverman SL. Evaluation of healthcare resource utilization and costs in employees with pain associated with diabetic peripheral neuropathy treated with pregabalin or duloxetine. *Journal of Medical Economics* 2010; 13(4): 738–47.
- Mark TL**, **Gibson TB**, McGuigan KA. The effects of antidepressant step-therapy protocols on pharmaceutical and medical utilization and expenditures. *American Journal of Psychiatry* 2010. Published online August 16, 2010.
- Mark TL**, **Montejano LB**, Kranzler HR, Chalk M, Gastfriend DR. Comparison of healthcare utilization among patients treated with alcoholism medications. *American Journal of Managed Care* 2010; 16(12): 879–88.
- Mark TL**, Vandivort-Warren R, Owens PL, Buck JA, **Levit KR**, **Coffey RM**, Stocks C. Psychiatric discharges in community hospitals with and without psychiatric units: How many and for whom? *Psychiatric Services* 2010; 61(6): 562–8.



## 2009

---

Amin AN, Lin J, **Lenhart G**, **Schulman KL**. Clinical and economic outcomes in patients at risk of venous thromboembolism receiving appropriate enoxaparin or unfractionated heparin prophylaxis. *Thrombosis and Haemostasis* 2009; 102(2): 321–6.

Citrome L, Reist C, **Palmer L**, **Montejano LB**, **Lenhart G**, Cuffel B, Harnett J, Sanders KN. Impact of real-world ziprasidone dosing on treatment discontinuation rates in patients with schizophrenia or bipolar disorder. *Schizophrenia Research* 2009; 115(2–3): 115–20.

**Gibson TB**, Lee TA, Vogeli C, Hidalgo J, Carls GS, Sredl K, DesHarnais S, **Marder WD**, et al. A four-system comparison of patients with chronic illness: The Military Health System, Veterans Health Administration, Medicaid, and commercial plans. *Military Medicine* 2009; 174(9): 936–943.

**Goetzel RZ**, **Baker KM**, **Short ME**, **Pei X**, **Ozminkowski RJ**, **Wang S**, **Bowen JD**, Roemer EC, Craun BA, Tully KJ, Baase CM, Dejoy DM, Wilson MG. First-year results of an obesity prevention program at the Dow Chemical Company. *Journal of Occupational and Environmental Medicine* 2009; 51(2): 125–138.

**Goetzel RZ**, **Carls GS**, **Wang S**, Kelly E, Mauceri E, Columbus D, Cavuoti A. The relationship between modifiable health risk factors and medical expenditures, absenteeism, short-term disability, and presenteeism among employees at Novartis. *Journal of Occupational and Environmental Medicine* 2009; 51(4): 487–99.

**Goetzel RZ**, Roemer EC, **Short ME**, **Pei X**, **Tabrizi MJ**, Liss-Levinson RC, Samoly DK, Luisi D, Quitoni K, Dumanovsky T, Silver LD, **Ozminkowski RJ**. Health improvement from a worksite health promotion private-public partnership. *Journal of Occupational and Environmental Medicine* 2009; 51(3): 296–304.

**Mark TL**, **Gibson TB**, McGuigan KA. The effects of antihypertensive step-therapy protocols on pharmaceutical and medical utilization and expenditures. *American Journal of Managed Care* 2009; 15(2): 123–31.

## 2008

---

**Chernew ME**, **Gibson TB**. Cost sharing and HEDIS performance. *Medical Care Research & Review* 2008; 65(6): 713-728.

**Chernew ME**, **Gibson TB**, Yu-Isenberg K, Sokol MC, Rosen AB, Fendrick AM. Effects of increased patient cost sharing on socioeconomic disparities in health care. *Journal of General Internal Medicine* 2008. Published online April 29, 2008.



**Mucha L**, Shaohung S, Cuffel B, McRae T, **Mark TL**, Del Valle M. Comparison of cholinesterase inhibitor utilization patterns and associated health care costs in Alzheimer's disease. *Journal of Managed Care Pharmacy* 2008; 14(5): 451–61.

## 2007

---

Brixner DI, **Lenhart G**, Young DC, Samuelson WM. The effect of fixed combination of fluticasone and salmeterol on asthma drug utilization, asthma drug cost, and episodes of asthma exacerbations. *Current Medical Research and Opinion* 2007; 23(11): 2887–95.

## 2006

---

**Gibson TB**, **Mark TL**, Axelsen K, **Baser O**, Rublee DA, McGuigan KA. Impact of statin copayments on adherence and medical care utilization and expenditures. *American Journal of Managed Care* 2006; 12(Spec): SP11–19.

**Gibson TB**, **Mark TL**, McGuigan KA, Axelsen K, **Wang S**. The effects of prescription drug copayments on statin adherence. *American Journal of Managed Care* 2006; Vol. 12(9): 509–517.

**Huse DM**, **Song X**, **Ozminkowski RJ**, **Maguire J**, Williams SA, Borok GM, McDonough K. Impact of rosuvastatin use on costs and outcomes in patients at high risk for cardiovascular disease in U.S. managed care and Medicare populations: A data analysis. *Clinical Therapeutics* 2006; 28(9): 1425–42.

Robinson RL, **Long SR**, **Chang S**, Able S, **Baser O**, Obenchain RL, Swindle RW. Higher costs and therapeutic factors associated with adherence to NCQA HEDIS antidepressant medication management measures: Analysis of administrative claims. *Journal of Managed Care Pharmacy* 2006; 12(1): 43–54.

## 2000–2005

---

**Gibson TB**, McLaughlin CG, Smith DG. A copayment increase for prescription drugs: The long-term and short-term effects on use and expenditures. *Inquiry* 2005; Vol 42(3): 293–310.

**Gibson TB**, **Ozminkowski RJ**, **Goetzel RZ**. The effects of prescription drug cost sharing: A review of the evidence. *The American Journal of Managed Care* 2005; 11: 730–740.

**Goetzel RZ**, **Ozminkowski RJ**, Baase CM, Billotti GM. Estimating the return-on-investment from changes in employee health risks on the Dow Chemical Company's health care costs. *Journal of Occupational and Environmental Medicine* 2005; 47(8): 759–768.



**Goetzel RZ, Ozminkowski RJ**, Bruno JA, Rutter KR, Isaac F, **Wang S**. The long term impact of Johnson & Johnson's Heath & Wellness program on employee health risks. *Journal of Occupational and Environmental Medicine* 2002; 44(5): 417–424.

**Goetzel RZ, Ozminkowski RJ**, Villagra VG, Duffy J. Return on investment in disease management: A review. *Health Care Financing Review* 2005; 26(4): 1–19.

**Mark TL**, McKenzie RS, Fastenau J, Piech CT. Retrospective observational study of patients with chemotherapy-related anemia receiving erythropoietic agents. *Current Medical Research and Opinion* 2005; 21(9): 1347–1354.

Matson Koffman DM, **Goetzel RZ**, Anwuri VV, Shore KK, Orenstein D, LaPier T. Heart healthy and stroke free: Successful business strategies to prevent cardiovascular disease. *American Journal of Preventative Medicine* 2005; 29(5 Suppl 1): 113–21.

**Ozminkowski RJ, Goetzel RZ**, Santoro J, Saenz BJ, Eley C, Gorsky B. Estimating risk reduction required to break even in a health promotion program. *American Journal of Health Promotion* 2004; 18(4): 316–325.

**Ozminkowski RJ, Goetzel RZ, Smith MW**, Cantor RI, Shaughnessy A, Harrison M. The impact of the Citibank, N.A., health management program on changes in employee health risks over time. *Journal of Occupational and Environmental Medicine* 2000; 42(5): 502–511.

**Ozminkowski RJ, Ling D, Goetzel RZ**, Bruno JA, Rutter KR, Isaac F, **Wang S**. Long-term impact of Johnson & Johnson's Heath & Wellness program on health care utilization and expenditures. *Journal of Occupational and Environmental Medicine* 2002; 44(1): 21–29.

vanVonne CJ, **Ozminkowski RJ, Smith MW**, Thomas EG, Kelley D, **Goetzel R**, Berg GD, Jain SK, Walker DR. What can a pilot congestive heart failure disease management program tell us about likely return on investment? A case study from a program offered to federal employees. *Disease Management* 2005; 8(6): 346–360.

For more information about any of these publications, please e-mail us at [cer@thomsonreuters.com](mailto:cer@thomsonreuters.com).